Ascidian Therapeutics
Founded 2020 · 48 employees on LinkedIn · 4 known investors
Ascidian Therapeutics is a biotechnology company developing RNA-based therapeutics, with a clinical focus that includes ophthalmology and inherited retinal diseases.
Investors · 4
Also in the syndicate · 2
Apple Tree PartnersleadApple Tree Partners (ATP)
Funding
SEC filings, press & company announcements$40M disclosed across 1 round · 2023
- $40MSeries A ExtensionNov 2023 · 4 sources
Apple Tree Partners (lead), Apple Tree Partners (ATP)
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Competitors · 2
by search overlapViridian Therapeutics23 shared keywordsViridian Therapeutics develops treatments for thyroid eye disease, a rare autoimmune condition affecting the eyes and orbit. The company focuses on clinical development and patient support programs in the biotech sector.
Bioworld17 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Ascidian Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Ascidian Therapeutics do?
- Ascidian Therapeutics is a biotechnology company developing RNA-based therapeutics, with a clinical focus that includes ophthalmology and inherited retinal diseases.
- Who are Ascidian Therapeutics's investors?
- Ascidian Therapeutics's investors include ATP, Scion Life Sciences.
- How much funding has Ascidian Therapeutics raised?
- Ascidian Therapeutics has disclosed $40M raised across 1 round.